JP2013535424A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013535424A5 JP2013535424A5 JP2013518748A JP2013518748A JP2013535424A5 JP 2013535424 A5 JP2013535424 A5 JP 2013535424A5 JP 2013518748 A JP2013518748 A JP 2013518748A JP 2013518748 A JP2013518748 A JP 2013518748A JP 2013535424 A5 JP2013535424 A5 JP 2013535424A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- compound according
- aryl
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 22
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- -1 nitro, amino Chemical group 0.000 claims 7
- 125000004104 aryloxy group Chemical group 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 206010046851 Uveitis Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 206010030043 Ocular hypertension Diseases 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- KVDYESNTWCANOH-UHFFFAOYSA-N 3-[1-[[5-bromo-2-(2-ethylbutoxy)phenyl]methyl]-5-methylpyrazol-3-yl]propanoic acid Chemical compound CCC(CC)COC1=CC=C(Br)C=C1CN1C(C)=CC(CCC(O)=O)=N1 KVDYESNTWCANOH-UHFFFAOYSA-N 0.000 claims 1
- MSILREZNZDUJJQ-UHFFFAOYSA-N 3-[1-[[5-bromo-2-(cyclopentylmethoxy)phenyl]methyl]-5-methylpyrazol-3-yl]propanoic acid Chemical compound CC1=CC(CCC(O)=O)=NN1CC1=CC(Br)=CC=C1OCC1CCCC1 MSILREZNZDUJJQ-UHFFFAOYSA-N 0.000 claims 1
- NTKCCANMCAOSKM-UHFFFAOYSA-N 3-[1-[[5-chloro-2-(2-ethylbutoxy)phenyl]methyl]-5-methylpyrazol-3-yl]propanoic acid Chemical compound CCC(CC)COC1=CC=C(Cl)C=C1CN1C(C)=CC(CCC(O)=O)=N1 NTKCCANMCAOSKM-UHFFFAOYSA-N 0.000 claims 1
- FWLNGQKMSQARPI-UHFFFAOYSA-N 3-[1-[[5-chloro-2-[(4-chlorophenyl)methoxy]phenyl]methyl]-5-methylpyrazol-3-yl]-n-(trifluoromethylsulfonyl)propanamide Chemical compound CC1=CC(CCC(=O)NS(=O)(=O)C(F)(F)F)=NN1CC1=CC(Cl)=CC=C1OCC1=CC=C(Cl)C=C1 FWLNGQKMSQARPI-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 206010017711 Gangrene Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020112 Hirsutism Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010020843 Hyperthermia Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010028735 Nasal congestion Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000005289 Neoplastic Cell Transformation Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010037368 Pulmonary congestion Diseases 0.000 claims 1
- 208000003782 Raynaud disease Diseases 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039094 Rhinitis perennial Diseases 0.000 claims 1
- 208000036071 Rhinorrhea Diseases 0.000 claims 1
- 206010039101 Rhinorrhoea Diseases 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 230000010100 anticoagulation Effects 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical class [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 208000015294 blood coagulation disease Diseases 0.000 claims 1
- 230000024279 bone resorption Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 230000036031 hyperthermia Effects 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 208000021267 infertility disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 210000003097 mucus Anatomy 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000011164 ossification Effects 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000008423 pleurisy Diseases 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 235000019260 propionic acid Nutrition 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36075510P | 2010-07-01 | 2010-07-01 | |
| US61/360,755 | 2010-07-01 | ||
| PCT/US2011/042729 WO2012003414A1 (en) | 2010-07-01 | 2011-07-01 | Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013535424A JP2013535424A (ja) | 2013-09-12 |
| JP2013535424A5 true JP2013535424A5 (enExample) | 2014-08-21 |
| JP5922116B2 JP5922116B2 (ja) | 2016-05-24 |
Family
ID=44514984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013518748A Active JP5922116B2 (ja) | 2010-07-01 | 2011-07-01 | 複数のプロスタグランジン受容体で作用する全般的な抗炎症反応をもたらす化合物 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US8492424B2 (enExample) |
| EP (1) | EP2588459B1 (enExample) |
| JP (1) | JP5922116B2 (enExample) |
| KR (1) | KR20130141434A (enExample) |
| CN (1) | CN103038219B (enExample) |
| AR (1) | AR082073A1 (enExample) |
| AU (1) | AU2011272716B2 (enExample) |
| BR (1) | BR112013000065A2 (enExample) |
| CA (1) | CA2804194C (enExample) |
| CL (1) | CL2013000002A1 (enExample) |
| CO (1) | CO6680625A2 (enExample) |
| ES (1) | ES2625355T3 (enExample) |
| MX (1) | MX2013000170A (enExample) |
| PH (1) | PH12013500121A1 (enExample) |
| RU (1) | RU2013102967A (enExample) |
| SG (1) | SG186886A1 (enExample) |
| TW (1) | TW201206891A (enExample) |
| WO (1) | WO2012003414A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12478503B2 (en) | 2009-05-18 | 2025-11-25 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| US8859606B2 (en) * | 2010-07-01 | 2014-10-14 | Allergan, Inc. | Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response |
| US9006450B2 (en) | 2010-07-01 | 2015-04-14 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical compositions and uses thereof |
| CA2860392C (en) * | 2011-12-21 | 2016-08-30 | Allergan, Inc. | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response |
| JP6132853B2 (ja) * | 2011-12-27 | 2017-05-24 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 全身性抗炎症反応を提供する、複数のプロスタグランジン受容体で作用する化合物 |
| EP2797894A1 (en) | 2011-12-27 | 2014-11-05 | Allergan, Inc. | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response |
| US9845465B2 (en) | 2012-08-15 | 2017-12-19 | University Of Virginia Patent Foundation | Compositions and methods for treating peripheral arterial disease |
| AU2014207266C1 (en) * | 2013-01-21 | 2018-11-08 | Allergan, Inc. | Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response |
| WO2015066541A1 (en) | 2013-10-31 | 2015-05-07 | Allergan, Inc. | 3-{1-[5-chloro-2-(2-ethylbutoxy)benzyl]-5-methyl-1h-pyrazol-3-yl}propanoic acid in crystalline form and methods for use thereof |
| CN106146400A (zh) * | 2015-03-20 | 2016-11-23 | 四川大学 | 苄基-1h-吡唑、苄基-1h-吡咯衍生物及其制备方法和用途 |
| US10462745B2 (en) | 2016-01-15 | 2019-10-29 | Google Llc | Systems and methods for extending battery life by monitoring device activity |
| CN107723304A (zh) * | 2016-08-10 | 2018-02-23 | 中国科学院上海生命科学研究院 | Prkar2a在炎症消退中的应用 |
| US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4826868A (en) * | 1986-05-29 | 1989-05-02 | Ortho Pharmaceutical Corporation | 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use |
| US6511999B2 (en) | 2000-09-14 | 2003-01-28 | Allergan, Inc. | Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2α antagonists |
| US7217725B2 (en) | 2000-09-14 | 2007-05-15 | Allergan, Inc. | Prostaglandin D2 antagonist |
| US7273883B2 (en) | 2000-09-14 | 2007-09-25 | Allergan, Inc. | Prostaglandin EP4 antagonist |
| CA2526013A1 (en) * | 2003-05-20 | 2004-12-02 | Merck Frosst Canada Ltd. | Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin d2 antagonists |
| DE602004011966T2 (de) | 2003-10-24 | 2009-02-12 | Glaxo Group Ltd., Greenford | Heterocyclylverbindungen |
| GB0508472D0 (en) * | 2005-04-26 | 2005-06-01 | Glaxo Group Ltd | Compounds |
-
2011
- 2011-06-28 US US13/170,467 patent/US8492424B2/en active Active
- 2011-07-01 MX MX2013000170A patent/MX2013000170A/es active IP Right Grant
- 2011-07-01 TW TW100123408A patent/TW201206891A/zh unknown
- 2011-07-01 PH PH1/2013/500121A patent/PH12013500121A1/en unknown
- 2011-07-01 SG SG2013000054A patent/SG186886A1/en unknown
- 2011-07-01 JP JP2013518748A patent/JP5922116B2/ja active Active
- 2011-07-01 EP EP11734222.0A patent/EP2588459B1/en active Active
- 2011-07-01 KR KR1020137002639A patent/KR20130141434A/ko not_active Withdrawn
- 2011-07-01 WO PCT/US2011/042729 patent/WO2012003414A1/en not_active Ceased
- 2011-07-01 AR ARP110102369A patent/AR082073A1/es unknown
- 2011-07-01 US US13/808,020 patent/US20140121258A1/en not_active Abandoned
- 2011-07-01 AU AU2011272716A patent/AU2011272716B2/en not_active Ceased
- 2011-07-01 RU RU2013102967/04A patent/RU2013102967A/ru not_active Application Discontinuation
- 2011-07-01 BR BR112013000065A patent/BR112013000065A2/pt not_active IP Right Cessation
- 2011-07-01 ES ES11734222.0T patent/ES2625355T3/es active Active
- 2011-07-01 CA CA2804194A patent/CA2804194C/en active Active
- 2011-07-01 CN CN201180038338.0A patent/CN103038219B/zh not_active Expired - Fee Related
-
2013
- 2013-01-02 CL CL2013000002A patent/CL2013000002A1/es unknown
- 2013-01-29 CO CO13016511A patent/CO6680625A2/es unknown
- 2013-05-20 US US13/898,254 patent/US20130253028A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013535424A5 (enExample) | ||
| JP2021508686A5 (enExample) | ||
| JP2012255002A5 (enExample) | ||
| JP2013542937A5 (enExample) | ||
| JP2016517432A5 (enExample) | ||
| JP2012515724A5 (enExample) | ||
| CN110573500A (zh) | N-(氮杂芳基)环内酰胺-1-甲酰胺衍生物及其制备方法和应用 | |
| JP2014513110A5 (enExample) | ||
| JP2014502979A5 (enExample) | ||
| JP2009542595A5 (enExample) | ||
| JP2014139226A5 (enExample) | ||
| EA201100423A1 (ru) | Новые бензамиды, их получение и их применение в качестве лекарственных средств | |
| JP2014525426A5 (enExample) | ||
| JP2015504909A5 (enExample) | ||
| JP2018513107A5 (enExample) | ||
| SI2743266T1 (en) | Protein kinase inhibitors (variants), their use in the treatment of oncological diseases and the pharmaceutical composition on their basis | |
| RU2010126063A (ru) | Производные 4-(2-амино-1-гидроксиэтил)фенола как агонисты в2 адренергического рецептора | |
| RU2018101080A (ru) | Регуляторы nrf2 | |
| JP2010523692A5 (enExample) | ||
| JP2013519680A5 (enExample) | ||
| JP2018521121A5 (enExample) | ||
| JP2015500883A5 (enExample) | ||
| JP2008505171A5 (enExample) | ||
| JP2011513366A (ja) | 新規な１−ベンジル−３−ヒドロキシメチルインダゾール誘導体及びそのＭＣＰ−１，ＣＸ３ＣＲ１及びｐ４０の発現に基づく疾病の治療への使用 | |
| CA2656057A1 (en) | Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain |